Latest Insider Transactions at Pulmonx Corp (LUNG)
This section provides a real-time view of insider transactions for Pulmonx Corp (LUNG). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Pulmonx Corp to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Pulmonx Corp's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 01
2021
|
Derrick Sung Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,600
+6.88%
|
-
|
|
May 24
2021
|
Geoffrey Beran Rose CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
4,797
-0.72%
|
$196,677
$41.34 P/Share
|
|
May 20
2021
|
Glendon E. French Iii |
SELL
Open market or private sale
|
Indirect |
1,000
-3.63%
|
$40,000
$40.75 P/Share
|
|
May 20
2021
|
Glendon E. French Iii |
SELL
Open market or private sale
|
Direct |
25,000
-1.02%
|
$1,025,000
$41.6 P/Share
|
|
May 18
2021
|
Geoffrey Beran Rose CHIEF COMMERCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
49,428
+22.93%
|
$49,428
$1.4 P/Share
|
|
May 10
2021
|
Geoffrey Beran Rose CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
4,797
-0.99%
|
$196,677
$41.68 P/Share
|
|
Apr 19
2021
|
Geoffrey Beran Rose CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
4,797
-3.8%
|
$206,271
$43.24 P/Share
|
|
Apr 15
2021
|
Glendon E. French Iii |
SELL
Open market or private sale
|
Indirect |
1,000
-3.5%
|
$43,000
$43.7 P/Share
|
|
Apr 15
2021
|
Glendon E. French Iii |
SELL
Open market or private sale
|
Direct |
25,000
-1.0%
|
$1,075,000
$43.92 P/Share
|
|
Apr 06
2021
|
Boston Scientific Corp > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
650,000
-14.01%
|
$27,950,000
$43.6 P/Share
|
|
Apr 06
2021
|
Derrick Sung Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,000
-0.75%
|
$235,000
$47.54 P/Share
|
|
Apr 05
2021
|
Derrick Sung Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,000
-1.09%
|
$240,000
$48.06 P/Share
|
|
Apr 05
2021
|
Geoffrey Beran Rose CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
4,797
-2.11%
|
$230,256
$48.03 P/Share
|
|
Mar 30
2021
|
Boston Scientific Corp > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
1,350,000
-22.54%
|
$54,000,000
$40.8 P/Share
|
|
Oct 05
2020
|
Staffan Lindstrand Director |
BUY
Conversion of derivative security
|
Indirect |
1,133,728
+23.5%
|
-
|
|
Oct 05
2020
|
Dana G Mead Jr. |
BUY
Open market or private purchase
|
Direct |
26,315
+50.0%
|
$499,985
$19.0 P/Share
|
|
Oct 05
2020
|
Dana G Mead Jr. |
BUY
Conversion of derivative security
|
Indirect |
1,524,109
+21.97%
|
-
|
|
Oct 05
2020
|
Georgia Melenikiotou |
BUY
Open market or private purchase
|
Direct |
26,315
+50.0%
|
$499,985
$19.0 P/Share
|
|
Oct 05
2020
|
Richard Ferrari |
BUY
Open market or private purchase
|
Direct |
13,157
+44.84%
|
$249,983
$19.0 P/Share
|
|
Oct 05
2020
|
Richard Ferrari |
BUY
Conversion of derivative security
|
Direct |
3,030
+50.0%
|
-
|
|
Oct 05
2020
|
Richard Ferrari |
BUY
Conversion of derivative security
|
Indirect |
1,221,489
+25.79%
|
-
|
|
Oct 05
2020
|
Daniel P Florin |
BUY
Open market or private purchase
|
Indirect |
15,789
+50.0%
|
$299,991
$19.0 P/Share
|
|
Oct 05
2020
|
Boston Scientific Corp > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
5,987,965
+11.16%
|
-
|